Skip to main content
. 2024 Sep 29;11(11):1441–1444. doi: 10.1002/mdc3.14215

Table 1.

Sample size calculations for a 12‐month randomized controlled trial of a disease modifying agent in an unstratified cohort versus a cohort with prognostic score >0.5

Prognostic score Baseline MDS‐UPDRS I + II; mean (SD) MDS‐UPDRS I + II change/year Power (%) Significance Sample size
All 18.91 (9.36) 3.05 80 0.05 296
>0.5 21.62 (9.29) 3.59 80 0.05 208

Abbreviations: MDS‐UPDRS, Movement Disorders Society—Unified Parkinson's Disease Score; SD, standard deviation.